SEC Form 4 · STOCK Act

Insider buys that paid off for the people who copied them.

$ZSTK

ZeroStack Corp.

+206.0%

Michael Heinrich, Executive Chair, bought $3.5M. Filed Jul 20, 6:31 PM ET.

COPIED JUL 21

$1,000 copied at the first price after the filing (Jul 21 open, $1.66) was $3,060 30 trading days later.

Example. Of 339 buys of $100K or more filed Jun 29 to Sep 11, the median lost 5.3% and 67.8% lost money over the same 30 trading days. Not investment advice.

Officers and directors must report their own stock purchases within two business days. We list every one, largest first, with what copying it would have returned.

A free account keeps a watchlist. No password: we email you a link.

RAPPSell

Rapport Therapeutics, Inc.

Abraham Ceesay · Chief Executive Officer

$64K−0.5%3d ago
RAPPBuy

Rapport Therapeutics, Inc.

Ramiro Sanchez · Director

$98K3d ago
RAPPBuy

Rapport Therapeutics, Inc.

Paul M Silva · Director

$100K4d ago
RAPPBuy

Rapport Therapeutics, Inc.

Wendy B. Young · Director

$100K+39.9%4d ago
RAPPBuy

Rapport Therapeutics, Inc.

Steven M Paul · Director

$974K+85.7%4d ago
RAPPBuy

Rapport Therapeutics, Inc.

John Maraganore · Director

$249K4d ago
RAPPBuy

Rapport Therapeutics, Inc.

Troy A. Ignelzi · Chief Financial Officer

$144K+55.0%5d ago
RAPPSell

Rapport Therapeutics, Inc.

Abraham Ceesay · Chief Executive Officer

$143K−1.0%Oct 8
RAPPSell

Rapport Therapeutics, Inc.

Cheryl Gault · Chief Operating Officer

$332K−6.7%Oct 1
RAPPSell

Rapport Therapeutics, Inc.

Abraham Ceesay · Chief Executive Officer

$87K−0.5%Sep 24
RAPPSell

Rapport Therapeutics, Inc.

Abraham Ceesay · Chief Executive Officer

$374K−1.8%Sep 9
RAPPSell

Rapport Therapeutics, Inc.

Abraham Ceesay · Chief Executive Officer

$938K−3.9%Aug 26
RAPPSell

Rapport Therapeutics, Inc.

Krishnaswamy Yeleswaram · Chief Development Officer

$2.5M−20.4%Aug 26
RAPPSell

Rapport Therapeutics, Inc.

Abraham Ceesay · Chief Executive Officer

$2.4M−9.6%Aug 12
RAPPSell

Rapport Therapeutics, Inc.

Abraham Ceesay · Chief Executive Officer

$93K−0.4%Jul 29
RAPPSell

Rapport Therapeutics, Inc.

Abraham Ceesay · Chief Executive Officer

$328K−1.5%Jul 15
RAPPSell

Rapport Therapeutics, Inc.

Cheryl Gault · Chief Operating Officer

$416K−6.3%Jul 1
RAPPSell

Rapport Therapeutics, Inc.

Abraham Ceesay · Chief Executive Officer

$327K−1.5%Jul 1
RAPPSell

Rapport Therapeutics, Inc.

Third Rock Ventures V, L.P. · 10% owner

$744K−0.3%May 28
RAPPSell

Rapport Therapeutics, Inc.

Third Rock Ventures V, L.P. · 10% owner

$5.4M−2.0%May 13
RAPPSell

Rapport Therapeutics, Inc.

Third Rock Ventures V, L.P. · 10% owner

$11.1M−4.0%May 11
RAPPSell

Rapport Therapeutics, Inc.

Third Rock Ventures V, L.P. · 10% owner

$17.2M−5.0%Apr 21
RAPPSell

Rapport Therapeutics, Inc.

Cheryl Gault · COO

$282K−6.0%Mar 31
RAPPSell

Rapport Therapeutics, Inc.

Cheryl Gault · COO

$58K−1.0%Mar 9
RAPPSell

Rapport Therapeutics, Inc.

Abraham Ceesay · CEO

$320K−2.0%Feb 19
RAPPSell

Rapport Therapeutics, Inc.

David Bredt · Chief Scientific Officer

$247K−2.0%Feb 19
RAPPSell

Rapport Therapeutics, Inc.

Abraham Ceesay · CEO

$285K−2.0%Jan 22
RAPPSell

Rapport Therapeutics, Inc.

David Bredt · Chief Scientific Officer

$228K−2.0%Jan 16
RAPPSell

Rapport Therapeutics, Inc.

David Bredt · Chief Scientific Officer

$197K−2.0%Jan 5
RAPPSell

Rapport Therapeutics, Inc.

Abraham Ceesay · CEO

$324K−2.0%Dec 18
RAPPSell

Rapport Therapeutics, Inc.

David Bredt · Chief Scientific Officer

$255K−2.0%Dec 16
RAPPSell

Rapport Therapeutics, Inc.

Cheryl Gault · COO

$150K−3.0%Dec 1
RAPPBuy

Rapport Therapeutics, Inc.

Reid M Huber · Director

$499KSep 15
RAPPBuy

Rapport Therapeutics, Inc.

Steven M Paul · Director

$1.0MSep 15
RAPPBuy

Rapport Therapeutics, Inc.

Wendy B. Young · Director

$79K+58.0%Sep 11
RAPPBuy

Rapport Therapeutics, Inc.

Troy A. Ignelzi · CFO

$101KMar 13
RAPPBuy

Rapport Therapeutics, Inc.

Wendy B. Young · Director

$61KMar 13
RAPPBuy

Rapport Therapeutics, Inc.

James Healy · Director

$1.1M+2.0%Jul 3
RAPPBuy

Rapport Therapeutics, Inc.

James Healy · Director

$9.5M+40.0%Jun 10

Filings come from SEC EDGAR within a minute of the SEC accepting them. Without Pro, each one unlocks 4 hours later. Not investment advice.

Questions

Where does the data come from?

Corporate insider trades come straight from SEC Form 4 filings, pulled from EDGAR within a minute of each filing. Congress trades come from STOCK Act disclosures. All of it is public and free to browse here, and Pro sees the newest filings first.

How often is it updated?

Every minute from 6 AM to 10 PM New York time on weekdays, the hours the SEC accepts filings. Pro sees each filing as it lands. Without Pro, a filing unlocks 4 hours after the SEC accepts it.

Is following insider trades legal?

Yes. Insiders are legally required to disclose their trades within a few days. Acting on those public disclosures is completely legal. Trading on private, non-public information is illegal, but that's a different thing.

What does the iPhone app add?

We're building an iPhone app that alerts you to new filings and, if you choose, copies a buy into your own brokerage after you approve it. It isn't out yet, and the waitlist is free.